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a  b  s  t  r  a  c  t
We  have  studied  bone  regenerative  medicine  to  employ  autologous  bone  marrow  stromal  cells  and
platelet-rich  plasma  as  tissue-engineered  osteogenic  materials.  Although  our  studies  have  been  success-
ful to  a certain  degree,  advancing  to  clinical  applications,  the  strategy  for  practical  use  of this  method  has
to be  changed,  because  the  environment  surrounding  bone regenerative  medicine  has  evolved  dramati-
cally. Therefore,  we  have  changed  our  focus  from  cells  to cell-conditioned  media,  and  we found  that  the
latter contains  growth  factors  and  matrices  released  from  the  cells  and  promotes  regeneration  of  tissues
by  recruiting  endogenous  stem  cells  and  precursor  cells,  and  thereby  started  clinical  research  based  on
these ﬁndings.  However,  the amount  of  regeneration  achieved  is minimal  (mm),  and  the  centimeter-scale
reconstruction  of segmental  bone  defects  is still  a challenge.  We  have  focused  our attention  on  distractiontem cell
onditioned medium
osteogenesis,  which  is an  excellent  model  for in  vivo  tissue  regeneration  of  segmental  defects,  and  we
have investigated  and  clariﬁed  its mechanisms  at a cellular  level,  based  on  tissue  regeneration  processes.
The strategy  has  been  investigated  to  promote  vascularization,  as  it should  precede  tissue  regeneration.
A  potential  approach  for enabling  tissue  regeneration  that  mimics  distraction  osteogenesis  without  using
a distraction  device  is discussed.
©  2015  Japanese  Stomatological  Society.  Published  by Elsevier  Ltd.  All  rights  reserved.ontents
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. Introduction of efﬁcacy and safety. Unfortunately, bone grafting can cause stress
at the donor site, limiting its application. Hence, bone regenerativeVarious materials such as calcium phosphate-based artiﬁcial
aterials, allogenic bone-derived materials, and heterogenic bones
re used to repair bone defects in the oral and maxillofacial regions.
owever, autologous bones are considered the best option in terms
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348-8643/© 2015 Japanese Stomatological Society. Published by Elsevier Ltd. All rights rmedicine has been studied extensively to overcome these limi-
tations. We  have been working in this ﬁeld and have attained a
certain level of success. However, defects that occur at the time
of mandibular segmental resection may  have characteristics that
are considerably different from those of small bone defects, in
terms of size, morphology, vascularization, the presence or absence
of investing soft tissues, and other factors. Hence, we  have not
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pplying bone regenerative medicine; thus, free vascularized
utologous grafting is required. In this article, we will consider
egenerative medicine-based methods to treat such large bone
efects, and also report the investigated design of a bone regen-
rative medicine approach and a plan for maxillomandibular
econstruction.
. Approaches to bone regenerative medicine
We  have performed translational research in bone regenerative
edicine using tissue-engineered osteogenic material (TEOM), a
omplex of autologous bone marrow stromal cells and platelet-rich
lasma, prepared from bone marrow aspirate and the peripheral
lood [1]. This effort was intended to differentiate osteogenic cells
rom the bone marrow stromal cells, growth factors contained
n the platelets, and the ﬁbrinous network (a type of gelatinized
lasma) to function at the bone defect site in the body as the three
mportant elements for tissue regeneration (i.e., cells, signals, and
caffolds, respectively). The standard method for the preparation
nd use of the TEOM is as follows. First, the eligibility of patients
hould be considered based on predetermined criteria, for example,
hether the patients have anemia or infections. Then, peripheral
lood samples are collected for the preparation of autoserum to
e used for cell culture. Either 200 or 400 mL  of blood should be
ollected once a month for 3 months, and the sera separated from
hese samples should be cryopreserved. Then, inserting a dedicated
entesis needle into the iliac crest under local anesthesia collects
 few milliliters of the bone marrow aspirate. Wall-adherent cells
re separated from the collected aspirate and cultured for about
 month. Once the cell count has reached a certain level, they are
llowed to differentiate into osteogenic cells for approximately 1
eek. Peripheral blood is then collected to prepare platelet-rich
lasma, which forms a complex with the cultured cells. Gelatiniza-
ion of this complex with thrombin and calcium chloride results in
he formation of the TEOM. The TEOM is prepared at the time of
se and is injected into or ﬁlled in the bone defect site. With regard
o the amount of regenerated bone obtained from the TEOM, when
he procedure was applied to the space made at the time of max-
llary sinus ﬂoor lifting in 16 sinuses in 12 patients, the height at
 years after the procedure was 8.8 mm ± 1.6 mm [2]. The proce-
ure was effective in patients with vertical ridge resorption [3] or
n alveolar cleft of >10 mm [4], and it was also possible to guide
nerupted teeth to a proper position. As described earlier, sufﬁcient
one regeneration could be obtained to support dental implants
sing the TEOM at the site of maxillary sinus ﬂoor lifting. How-
ver, some studies reported that the bones regenerated if blood
lots were maintained [5]; hence, the application of the procedure
eeds to be reexamined.
. Changes in the environment surrounding bone
egenerative medicine
As the number of clinical research studies based on regenera-
ive medicine increases, the regulation of regenerative medicinal
pplications should be considered. In 2006, the Ministry of Health,
abour and Welfare, Japan, established the “Guidelines on clinical
esearch using human stem cells” (hereafter referred to as “guide-
ines”) [6]. Before this, our institution consisted of a cell-processing
acility that had sufﬁcient equipment and a quality control system
o ensure safety, and it was  accredited by the International Organi-
ation for Standardization (ISO 13485) [7]. Because the guidelines
re applicable only to research to be started after 2006, and not to
hat had been started before 2006, we decided to reconsider the
ontent of our prior research based on the new guidelines.ional 13 (2016) 15–19
Human allogenic mesenchymal stem cells were ﬁrst marketed
in 2010 for bone augmentation in the oral and maxillofacial regions
in the United States of America (US) in 2010 [8]. In Japan, a bovine-
derived bone substitute was  approved for periodontal use in 2011,
almost 20 years after the approval in the US and Europe [9]. These
products were sold for tens of thousands of yen; especially, the
TEOM products cost >500,000 yen for the material alone. Fur-
thermore, the cost of construction of the initial facility for the
aforementioned cell processing was  200 million yen, and the annual
maintenance and operation costs exceeded 60 million yen. Hence,
the cost of TEOM was estimated to be exorbitant. New cell prepara-
tion devices, such as isolators or automatic culture machines, that
do not require the extensive cell-processing facilities and can be
installed for a cost of several tens of millions of yen, have been
developed; thus, the expenses for establishing and operating facil-
ities have been reduced. However, in any case, considering the
cost-effectiveness of the materials, there is little hope for practical
use of the TEOM.
As the number of studies on bone regeneration from the TEOM
increases, the efﬁcacy of this method has gradually become clear.
Bone regeneration using the TEOM depends greatly on the mor-
phology of defects. When the number of bony walls surrounding the
defect decreases, the amount of regenerated bone also decreases
proportionately; in addition, the TEOM is not effective for segmen-
tal defects. No speciﬁc relationship has been observed between the
number of cells applied to the bone defect site and the amount
of regenerated bone. Furthermore, cells that are autologous but
are cultured ex vivo have substantially lower survival rates after
introduction into the body [10,11], and these cells often regener-
ate tissues indirectly rather than directly, that is, endogenous stem
cells and precursor cells recruited by paracrine effects regenerate
the tissue at a higher rate.
4. Changes in the strategy for realizing bone regenerative
medicine
As legal regulations on regenerative medicine become more
stringent, burdens on facilities and personnel, and costs for cell
culture have increased. Moreover, the mechanisms of tissue regen-
eration have become clearer. We thus have had to change our
strategy for bone regenerative medicine (Fig. 1).
A German group [12], conducting studies similar to ours using
osteogenic cells derived from the periosteum, demonstrated the
limitations of bone regeneration [13]. In order to avoid the prob-
lems associated with cell culture, researchers began to apply
bone regenerative medicine without the use of cell culture [14].
Their new method was intended to obtain mononuclear cells
by centrifuging the bone marrow aspirate and to apply the
mononuclear cells together with bovine-derived bone substitute
to the bone defect site. This procedure can be completed in the
operating room without a specialized cell-processing facility or
culture.
We have investigated a different type of bone regenerative
medicine wherein cell culture is performed but the cells are not
introduced into the body. Here, we have focused on the appli-
cation of cell-conditioned medium rather than conditioned cells.
The cell-conditioned medium contains growth factors and sub-
strates that are released from the cells. If endogenous stem cells
and precursor cells could be recruited by the application of the con-
ditioned medium to the bone defect site, bone regeneration may
be obtained. Because this procedure does not include the intro-
duction of processed cells into the body, it is outside the scope of
the guidelines. In addition, if active components in the conditioned
medium are identiﬁed, and their formulation becomes possible in
H. Hibi / Oral Science International 13 (2016) 15–19 17
Fig. 1. Changes in strategy for realizing bone regenerative medicine. The design
of  bone regenerative medicine approaches based on existing concepts of regener-
ative medicine needs to be reconsidered because of the tightening of regulations
regarding regenerative medicine, burdens related to cell culture, limitations of the
amount of regeneration, and other factors. Cell-conditioned media contain growth



































Fig. 2. Two  extremely different situations of bone defects. The area to be treated in
the case of maxillary sinus ﬂoor lifting may  be only on the millimeter scale, whereas
segmental defects can be centimeters long/wide. In addition, segmental defects may
have circulation disorders because of preoperative irradiation or resection of soft
tissue. Furthermore, chewing and swallowing inhibit the postoperative local rest.ells  can be recruited by the conditioned medium, tissue regeneration will occur. If
ctive components in the conditioned medium are identiﬁed and can be formulated,
arious problems associated with cell culture will be avoided.
he future, various problems associated with cell culture will be
voided.
. Bone regenerative medicine using cell-conditioned
edia
Approximately 2000 proteins have been identiﬁed by com-
rehensive analysis of the components of bone marrow- and
ental pulp-derived stem cell-conditioned media. Growth fac-
ors and extracellular matrices associated with bone formation,
uch as collagen-1, bone sialoprotein-2, osteopontin, osteocal-
in, ﬁbronectin, vascular endothelial growth factor (VEGF)-A,
nd decorin, were identiﬁed in these proteins [15]. Interest-
ngly, commercially available bone morphogenetic protein (BMP),
latelet-derived growth factor-BB, and ﬁbroblast growth factor-
, which are reported to be effective in bone formation, were not
etected. When the conditioned medium was applied with agarose
el or collagen sponge as a scaffold to the bone defect site, stem
ells and precursor cells migrated, resulting in bone regeneration
ecause of vascularization from the tissue bed [16–20]. This ﬁnding
emonstrates that the mechanism of bone regeneration with the
onditioned medium has already been used in clinical research.
nitial efforts to regenerate bones examined the combined use of
utologous cell-conditioned media and a calcium phosphate-based
one substitute; however, this has now advanced to the use of
llogenic cell-conditioned media.
. Study on maxillomandibular reconstruction
The defect made during mandibular segmental resection is com-
letely different from that made during maxillary sinus ﬂoor lifting;
herefore, simple application of the bone regenerative medicine
escribed above will not be sufﬁcient. The area to be treated in
he case of maxillary sinus ﬂoor lifting may  be only on the millime-
er scale, whereas segmental defects can be centimeters long/wide
Fig. 2). In addition, segmental defects may  have circulation disor-
ers, because of preoperative irradiation or resection of soft tissue.Reconstruction of centimeter-scale segmental bone defects is still a challenge.
Furthermore, chewing and swallowing inhibit the postoperative
local rest. Indeed, implants must allow for the restoration of chew-
ing function. Autologous grafting using a free vascularized bone
ﬂap is generally applied to satisfy these conditions. This method
can provide immediate recovery of vascularization of the grafted
tissue, and thus has wide applications. It also permits free forma-
tion of the soft tissue. Recently, it has become possible to perform
correct bone ﬂap collection, morphological restoration, and implant
placement simultaneously using a computer simulation guide [21].
However, the drawback of this method is that the invasive burden
on the donor site is still too large and unavoidable.
An attempt to ectopically prepare bone among vascularized
bone ﬂaps was  made by a German group [22]. The group subcu-
taneously implanted a mixture in which autologous bone marrow
and BMP-7 were added to a bovine bone-derived bone block
in the back. The implanted mixture was used for mandibular
reconstruction as a vascularized bone ﬂap after ossiﬁcation and
vascularization. This report is interesting in that it demonstrated
not only morphological restoration but also the activity of the
bone ﬂap tissue before and after the operation by scintigraphic
means. This method is advantageous because the donor site can
be changed at will, and invasiveness can be reduced; however,
it requires embedding surgery associated with the bone ﬂap and
appropriate ossiﬁcation time.
An attempt to regenerate bones using a more simple method
was made by a US group [23]. In this attempt, the authors impreg-
nated BMP-2, which had just become available, in a collagen sponge
and applied it to the mandibular segmental defect site main-
tained on a titanium plate. Several months after its application,
sufﬁcient ossiﬁcation occurred in all 14 patients. Cases in which
implants were embedded in the regenerated bone in two stages
were also presented. The major advantage of this method was  that
it did not require transplant materials. However, because all of
the patients presented with benign diseases with intact perios-
teum, the extent to which the condition of the surrounding soft
tissue was  involved was  unclear. Therefore, the obtained results
could not be compared with the abovementioned results using
the same standards. Mandibular segmental defects are outside
the indication of BMP-2. The US Food and Drug Administration
warned that signiﬁcant swelling due to responsive inﬂammation
had occurred after its application to the cervical spine, leading
to airway constriction or obstruction [24]. Because a similar side
effect may  occur, off-label use of BMP-2 in the mandible will not be
possible.
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Fig. 3. Our scheme for maxillomandibular reconstruction. Will it be possible to
perform bone regeneration that mimics distraction osteogenesis without using a











































mration by applying an appropriately compounded formulation to a bone defect site
t  the appropriate time?
. Reexamination of bone regeneration in the body for
axillomandibular reconstruction
Bone lengthening using distraction osteogenesis is an alterna-
ive method of maxillomandibular reconstruction that is thought
o be more secure and physiological, and it can also induce max-
mum tissue regeneration capacity. However, the long treatment
uration required for distraction osteogenesis continues to ham-
er the application of this method in the clinical setting. In order
o solve this problem, we considered the immature tissue in the
istraction gap as a scaffold, that is, one of the three elements
equired for tissue regeneration, and tried to supplement the two
ther insufﬁcient elements using the TEOM. This promoted ossi-
cation of the distraction gap, shortened the treatment duration,
nd improved the three-dimensional shape of the osseous regen-
rate (i.e., width and height) [25–28]. Furthermore, we were able
o conﬁrm that the application of the TEOM to the gap between the
ontacting transport bony segments resulted in their fusion. How-
ver, on the basis of the guidelines published in 2006, as described
arlier, we discontinued our pursuit of this method and instead
ried to explore the mechanism based on the tissue regenera-
ion process through distraction osteogenesis [29]. A mouse tibial
istraction model was used, and standard and double distraction
peeds were tested. Bone regeneration was not substantial when
he standard speed was doubled, because of the reduced num-
ers of both vascular endothelial cells and vascular endothelial
recursor cells in the distraction gap, preventing the occurrence
f angiogenesis. Thus, we  were able to clarify the mechanisms
ssociated with distraction osteogenesis. When we administered
tromal cell-derived factor (SDF)-1, a representative factor that
ecruits the cells to the distraction gap, we found a series of pro-
esses in the context of doubled standard distraction speed as
ollows: migration of the cells to the distraction gap, occurrence
f angiogenesis, migration of the vascular smooth muscle cells and
aturation of blood vessels, increase of blood ﬂow volume, and
one regeneration. Then, we also performed a similar test using
tem cell-conditioned media [30]. When the conditioned medium
as administered to the double-speed distraction gap of the same
odel, the vascular endothelial cells and vascular endothelial pre-ursor cells migrated to the distraction gap to cause angiogenesis.
n addition, the vascular smooth muscle cells migrated to the
istraction gap to promote maturation of blood vessels, and the
esenchymal stem cells migrated to promote their differentiationional 13 (2016) 15–19
into osteoblasts, resulting in bone regeneration. We  also iden-
tiﬁed the main cytokines involved in these individual processes
and examined culture conditions [31]. The conditions of the cells
changed depending on the culture environment. The cells released
corresponding factors or matrices when exposed to stresses, such
as hypoxic or low-nutrient conditions. We  therefore focused our
attention on the conditioned medium obtained when the cells
were cultured at a lower oxygen partial pressure. This conditioned
medium elevated the migration and tube formation capacities of
the vascular endothelial cells compared with the effects from the
culture at standard partial oxygen pressure. However, neither of
these conditioned media elevated the calciﬁcation ability of the
osteoblasts. When the conditioned media obtained from hypoxic
cultures were administered to the double-speed distraction gap of
the same model, vascular maturation by vascular smooth muscle
cells progressed, and bone regeneration was enhanced as com-
pared with the effects from cells cultured at standard oxygen partial
pressure.
8. Summary and future perspectives in maxillomandibular
reconstruction
We  can conclude from the above discussion that bone regen-
eration at the distraction gap is promoted by vasculature-forming
cells rather than bone-forming cells. Therefore, the key to achiev-
ing successful bone regeneration is the recruitment and function
of vasculature-forming cells. Ilizarov, a pioneer of bone length-
ening using distraction osteogenesis, described the importance of
vascularization in distraction osteogenesis in a prior report [32].
Later, research at the tissue level demonstrated that the vascu-
lar formation precedes bone formation in the distraction gap [33];
we have further evaluated these processes at the cellular level.
Various attempts have been made to promote ossiﬁcation at the
distraction gap, which is the main challenge of distraction osteo-
genesis. These attempts have included hyperbaric oxygenation,
electrical stimulation, administration of growth factors, and, in our
case, administration of the TEOM; certain degrees of successful
bone regeneration have been achieved. Representative growth fac-
tors used for bone regeneration include BMP  and VEGF. Although
these growth factors exhibit strong activity, their efﬁcacies are
limited, even if the concentrations are increased, because their
sites of action are ﬁxed. By contrast, the conditioned media of
stem cell cultures contain many active components, and although
the amounts of individual components may  be minute, the com-
bined functions act at multiple stages of the tissue-forming process,
exerting additive and/or synergistic effects. In addition, the sub-
stances released from the cells during physiological responses may
be mediated by intentionally changing the culture environment,
and they would be expected to exert intended effects on bone
regeneration. An equation describing optimal cell-conditioned
medium for promoting tissue regeneration, considering the cell
species and culture environment as variables, will eventually be
found, and appropriate methods for the application of such condi-
tioned media will then be required. In the case of large segmental
defects, tissue regeneration that mimics distraction osteogene-
sis may  be obtained by the sequential application of a series of
simultaneous equations; for example, tissue regeneration mim-
icking distraction osteogenesis may  be expected by injecting the
conditioned medium obtained in the desired environment or
by sequentially injecting optimally compounded active compo-
nents (Fig. 3). As a scaffold, tricalcium phosphate is considered
suitable and capable of facilitating perfectly formed reconstruc-
tion with three-dimensional laminating technology [34]. We  plan
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